FIELD: medicine.
SUBSTANCE: this description relates to combinations of NMDA modulators and atypical antipsychotics. In this description, for example, methods are proposed for the treatment of schizophrenia, bipolar disorder and/or cognitive impairment (disorder) in a patient, to which NMDAR antagonist was sub-chronically administered, including the administration of rapastinel and atypical antipsychotic.
EFFECT: obtaining a combination for the treatment of mental disorders.
4 cl, 7 ex, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| KETAMINE PRODRUGS, COMPOSITIONS AND APPLICATIONS THEREOF | 2019 |
|
RU2756512C1 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING AN ANTIPSYCHOTIC DRUG AND A VMAT2 INHIBITOR, AND THEIR USE | 2015 |
|
RU2757221C2 |
| NMDA RECEPTOR MODULATORS AND THEIR APPLICATION | 2012 |
|
RU2621049C2 |
| KETAMINE PAMOATE AND USE THEREOF | 2020 |
|
RU2825336C2 |
| TREATMENT OF NEUROLOGICAL DISORDERS | 2017 |
|
RU2765868C2 |
| ORGANIC COMPOUNDS | 2018 |
|
RU2777366C2 |
| COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | 2015 |
|
RU2733756C2 |
| NEW COMPOSITIONS FOR PREVENTING OR TREATING DEGENERATIVE DISEASES OF CENTRAL NERVOUS SYSTEM | 2010 |
|
RU2581058C2 |
| CYTOTOXIC PEPTIDES AND ANTIBODY-DRUG CONJUGATES THEREOF | 2012 |
|
RU2586885C2 |
| 3R,4S 3-[4-(4-FLUOROPHENYL)-4-HYDROXYPIPERIDIN-1- YL)CHROHAN-4,7-DIOL, OPTICAL ISOMERS THEREOF AND PHARMACEUTICAL COMPOSITION BASED THEREON, AND METHOD OF MEDICAL TREATMENT | 1994 |
|
RU2126404C1 |
